featured
Venetoclax Plus LDAC for Newly Diagnosed AML Ineligible for Intensive Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Venetoclax Plus LDAC for Newly Diagnosed AML Ineligible for Intensive Chemotherapy: A Phase 3 Randomized Placebo-Controlled Trial
Blood 2020 Jun 11;135(24)2137-2145, AH Wei, P Montesinos, V Ivanov, CD DiNardo, J Novak, K Laribi, I Kim, DA Stevens, W Fiedler, M Pagoni, O Samoilova, Y Hu, A Anagnostopoulos, J Bergeron, JZ Hou, V Murthy, T Yamauchi, A McDonald, B Chyla, S Gopalakrishnan, Q Jiang, W Mendes, J Hayslip, P PanayiotidisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.